Altimmune Inc (NAS:ALT)
$ 7.33 -0.06 (-0.81%) Market Cap: 519.71 Mil Enterprise Value: 342.50 Mil PE Ratio: 0 PB Ratio: 3.00 GF Score: 30/100

Altimmune Inc at Jefferies Healthcare Conference Transcript

Jun 09, 2023 / 12:30PM GMT
Release Date Price: $4 (-2.20%)
Roger Song
Jefferies - Analyst

Okay. Welcome, everyone. Day three, last day, 2023 Jefferies Healthcare Conference. My name is Roger Song, one of the senior analyst who covers SMID-cap biotech here and our next presenting company is Altimmune.

With me today is CEO, Vipin, and CMO, Scott. Good to see you.

Vipin Garg
Altimmune, Inc. - President, CEO & Director

Good to see you too.

Roger Song
Jefferies - Analyst

Okay. Maybe just get the start, Vipin, maybe you can give us updated elevator pitch for folks even they already know about Altimmune or particularly for the people new to the story.

Vipin Garg
Altimmune, Inc. - President, CEO & Director

Absolutely. Well, first of all, thank you for inviting us and excited to be here. So at Altimmune, we are developing peptide-based therapeutics for obesity and for liver diseases. We've got our lead program is a GLP-1 glucagon dual receptor agonist that we're developing for obesity and for NASH.

For

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot